摘要
目的观察国产替吉奥胶囊联合多西他赛治疗晚期食管癌的临床疗效和安全性。方法选择31例晚期食管癌患者,予替吉奥80 mg/m2,分2次,餐后口服,d1~d14,联合应用多西他赛25 mg/m2静脉滴注1 h,d1、d8,21 d为1个周期。观察临床疗效、不良反应,以及随访情况。结果完全缓解（CR）2例,部分缓解（PR）11例,病情稳定（SD）8例,病情进展（PD）10例,临床总缓解率（CR＋PR）为41.9%,疾病控制率（CR＋PR＋SD）为67.7%。毒副反应主要为Ⅰ~Ⅲ度骨髓抑制、手足综合征、腹泻、轻度肝功能损伤等。中位疾病进展时间（mTTP）7.4个月,1年生存率74.2%。结论替吉奥胶囊联合多西他赛治疗晚期食管癌有一定疗效,患者耐受性好,值得临床进一步研究。
Objective To observe the therapeutic effect and drug tolerance of S-1 capsule combined with Docetaxel on patients with advanced esophageal cancer.Methods Thirty-one patients with advanced esophageal cancer were treated with S-1 capsule 80 mg/m2,twice daily for 14 days and Docetaxel 25 mg/m2 intravenously 1 hour on day 1 and 8.The chemotherapy was repeated every 21 days.The therapeutic effect,adverse reactions and follow-up condition were observed after treatment.Results Two cases showed complete remission（CR）,11 cases partial remission（PR）,8 cases stable disease（SD）,10 cases progressive disease（PD）.Response rate（CR＋PR） was 41.9%,illness control rate（CR＋PR＋SD） was 67.7%.The major adverse events were grade Ⅰto Ⅲ myelosuppression,hand-foot syndrome and diarrhea.Some patients had the damage of liver function.The median time to progress（mTTP） was 7.4 months.The median 1-year survival rate was 74.2%.Conclusion The combination of S-1 capsule and Docetaxel is an effective and well-tolerated regimen for the patients with advanced esophageal cancer.
出处
《实用临床医药杂志》
CAS
2011年第17期102-104,共3页
Journal of Clinical Medicine in Practice
关键词
食管癌
替吉奥
多西他赛
化疗
esophageal cancer
S-1
Docetaxel
chemotherapy
